Xenotropic murine leukemia virus-related virus (XMRV), a gammaretrovirus, has been isolated from human prostate cancer tissue and from activated CD4(+) T cells and B cells of patients with chronic fatigue syndrome, suggesting an association between XMRV infection and these two diseases.
Since APOBEC3G (A3G) and APOBEC3F (A3F), which are potent inhibitors of the murine leukemia virus and Vif-deficient human immunodeficiency virus type 1 (HIV-1), are expressed in human CD4(+) T cells and B cells, we sought to determine how XMRV evades suppression of replication by APOBEC3 proteins.
We found that expression of A3G, A3F, or murine A3 in virus producing cells resulted in their virion incorporation, inhibition of XMRV replication, and G-to-A hypermutation of the viral DNA with all three APOBEC3 proteins.
Quantitation of A3G and A3F mRNA indicated that compared to human T-cell lines CEM and H9, prostate cell lines LNCaP, and DU145 exhibited 50% lower A3F mRNA levels, whereas A3G expression in 22Rv1, LNCaP and DU145 cells was nearly undetectable. A low frequency of XMRV proviral genomes in LNCaP and DU145 cells were hypermutated with mutation patterns consistent with A3F activity.
XMRV proviral genomes were extensively hypermutated upon replication in A3G/A3F-positive T cells (CEM and H9) but not in A3G/A3F-negative cells (CEM-SS). We also observed that XMRV replication was susceptible to nucleoside reverse transcriptase (RT) inhibitors AZT and tenofovir, and integrase inhibitor, raltegravir.
In summary, the establishment of XMRV infection in patients may be dependent on infection of A3G/A3F-deficient cells and that cells expressing low levels of A3G/A3F, such as prostate cancer cells, may be ideal producers of infectious XMRV.
Furthermore, anti-HIV-1 drugs AZT, tenofovir, and raltegravir may be useful for treatment of XMRV infection.
Source: Journal of Virology, Mar 24, 2010. PMID: 20335265, by Paprotka T, Venkatachari NJ, Chaipan C, Burdick R, Delviks-Frankenberry KA, Hu WS, Pathak VK. HIV Drug Resistance Program, National Cancer Institute at Frederick, Viral Mutation Section and Viral Recombination Section, Frederick, Maryland, USA. [Email: firstname.lastname@example.org]